2seventy Bio shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform and raised its price target from $5 to $18.
Portfolio Pulse from Benzinga Newsdesk
2seventy Bio's stock is trading higher following an upgrade by Leerink Partners from Market Perform to Outperform, with a significant increase in the price target from $5 to $18.
January 31, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
2seventy Bio (TSVT) has received a positive analyst rating upgrade from Leerink Partners, changing from Market Perform to Outperform, and a significant price target increase from $5 to $18.
The upgrade by Leerink Partners to an Outperform rating, coupled with a substantial increase in the price target for 2seventy Bio, suggests a strong vote of confidence in the company's future performance. This is likely to be viewed positively by investors and could lead to a short-term increase in the stock price as market sentiment improves.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100